• Educational resources
  • Events
  • Expert Panel
  • Learning Hub
    Learning Hub
    • EoE Learning Hub
    • Chronic Spontaneous Urticaria Learning Hub
    • COPD Learning Hub
    • Rhinology Learning Hub
    • Type 2 Asthma Learning Hub
    • Prurigo Nodularis Learning Hub
    • Atopic Dermatitis Learning Hub
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT
  • Contact us

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region
Type 2 Inflammation

Exacerbations Lead to Worsening Lung Function

Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.
Mario Castro
MD, MPH
Mario Castro
2 minutes

Related resources

Type 2 Inflammation Underpins Pediatric Severe Asthma

Type 2 Inflammation Underpins Pediatric Severe Asthma

5 min
Infographic
Eosinophils as a Biomarker for Type 2 Asthma

Eosinophils as a Biomarker for Type 2 Asthma

15 min
expert video
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

24 min
expert video
What Are the Key Inflammatory Processes in Patients with COPD?

What Are the Key Inflammatory Processes in Patients with COPD?

2 min
expert video
FeNO as a Biomarker for Type 2 Asthma

FeNO as a Biomarker for Type 2 Asthma

16 min
expert video
IgE as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma

14 min
expert video
Pediatric Asthma Patient Case Tool: Ash

Pediatric Asthma Patient Case Tool: Ash

5 min
interactivity
Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

5 min
Infographic
Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

19 min
expert video
ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD

ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD

20 min
expert video
Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

4 min
videoanimation
Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind

Managing Type 2 Inflammatory Diseases: Multidisciplinary Frame of Mind

6 min
expert video
Clinical Manifestations Associated With Airway Remodeling in Asthma

Clinical Manifestations Associated With Airway Remodeling in Asthma

2 min
expert video
Impact of Exacerbations in COPD

Impact of Exacerbations in COPD

2 min
expert video
Role of Type 2 Cytokines in Asthma and COPD

Role of Type 2 Cytokines in Asthma and COPD

2 min
expert video
Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

5 min
expert video
Mucus Plugging as a Potential Target in Asthma Management

Mucus Plugging as a Potential Target in Asthma Management

3 min
expert video
Multifaceted Role of IL-13 in Airway Remodeling

Multifaceted Role of IL-13 in Airway Remodeling

3 min
expert video
Pediatric Asthma Trajectory and Clinical Remission

Pediatric Asthma Trajectory and Clinical Remission

4 min
expert video
Screen depicting a mucus plug in the airways

A view into the Airway: The Pathophysiology and Clinical Relevance of Mucus Plugs in Asthma

4 min
videoanimation
2025 ADVENT Forum | Joint Plenary Session: A View into the Life of Our Patients Video

2025 ADVENT Forum | Joint Plenary Session: A View into the Life of Our Patients Video

46 min
expert video
The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

The Path to Nodules: Type 2 Inflammation at the Core of Chronic Itch and Fibrosis in Prurigo Nodularis

11 min
expert video
ERS 2024 | IL-33 A Promising Target

ERS 2024 | IL-33 A Promising Target

7 min
expert video
ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

15 min
expert video
AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

AANP 2025 | Atopic Diseases & a Case-Based Panel of Nurse Practitioners

45 min
videoanimation
2025 ADVENT Forum | Potential for Disease Modification in the Airway

2025 ADVENT Forum | Potential for Disease Modification in the Airway

45 min
expert video
GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

5 min
interactivity
Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

5 min
interactivity
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

3 min
Infographic
Compounded Burden of Co-existing Type 2 Airway Diseases

Compounded Burden of Co-existing Type 2 Airway Diseases

4 min
expert video
Spotlight on Type 2 Inflammation in the Upper and Lower Airways

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

4 min
expert video
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

3 min
expert video
Why Is It Important to Assess Lung Function in Pediatric Asthma?

Why Is It Important to Assess Lung Function in Pediatric Asthma?

5 min
interactivity
Airway Hyperresponsiveness In Asthma Is Mainly Driven By  Components Of Type 2 Inflammation

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

5 min
interactivity
The Burden in Patients with CRSwNP and Coexisting Asthma

The Burden in Patients with CRSwNP and Coexisting Asthma

8 min
expert video
ERS 2025 | Type 2 Severe Asthma "Unplugged": Reducing Mucus to Improve Long-term Patient Outcomes

ERS 2025 | Type 2 Severe Asthma "Unplugged": Reducing Mucus to Improve Long-term Patient Outcomes

52 min
videoanimation
How FeNO Measurement Can Improve Severe Asthma Management — Presented in Spanish by Dr. Miguel Lanz

How FeNO Measurement Can Improve Severe Asthma Management — Presented in Spanish by Dr. Miguel Lanz

7 min
expert video
The Role of IL-4 and IL-13 in CSU Pathogenesis

The Role of IL-4 and IL-13 in CSU Pathogenesis

10 min
interactivity
Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

5 min
interactivity
EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime

EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime

27 min
expert video
ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

21 min
Podcast
The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers

The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers

4 min
videoanimation
ADVENT On Air | Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

ADVENT On Air | Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

21 min
Podcast
IL-4 Is the Primary Cytokine That Drives Th2 Cell Polarization and Amplifies Type 2 Inflammation

IL-4 Is the Primary Cytokine That Drives Th2 Cell Polarization and Amplifies Type 2 Inflammation

3 min
expert video
How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?

How Does Type 2 Inflammation Manifest in Chronic Diseases Across Different Organs?

4 min
expert video
Type 2 Inflammatory Diseases Can Negatively Impact Patients and Their Caregivers

Type 2 Inflammatory Diseases Can Negatively Impact Patients and Their Caregivers

2 min
expert video
Distinct Mechanisms Drive Inflammation and Itch in Chronic, Type 2 Inflammatory Diseases

Distinct Mechanisms Drive Inflammation and Itch in Chronic, Type 2 Inflammatory Diseases

4 min
expert video
Coexisting Type 2 Inflammatory Diseases Can Add to the Patient Overall Disease Burden

Coexisting Type 2 Inflammatory Diseases Can Add to the Patient Overall Disease Burden

2 min
expert video
Type 2 Inflammatory Disease: What Are the Mechanisms that Contribute to the Development of Other Atopic Comorbidities?

Type 2 Inflammatory Disease: What Are the Mechanisms that Contribute to the Development of Other Atopic Comorbidities?

4 min
expert video
Itch in Chronic Inflammatory Skin Diseases: Histaminergic and Nonhistaminergic Mechanisms and Role of IL-4 as a Central Orchestrator in Promoting Neuronal Sensitization

Itch in Chronic Inflammatory Skin Diseases: Histaminergic and Nonhistaminergic Mechanisms and Role of IL-4 as a Central Orchestrator in Promoting Neuronal Sensitization

3 min
expert video

Learning objectives

  • Understand how repeated exacerbations in COPD patients lead to a progressive decline in lung function
  • Understand that exacerbations can lead to the occurrence of future exacerbations future exacerbations

Description

This video highlights the critical impact of exacerbations on lung function in COPD patients. It explains how repeated exacerbations lead to a progressive decline in lung function, with around 25% of patients never returning to their baseline after a severe episode. 

Tags
exacerbationslung function
MAT-GLB-2500889 - 1.0 - 04/2025

About this expert

Pulmonology

Mario Castro

MD, MPH

Chief, Pulmonary, Critical Care and Sleep Medicine; Vice Chair for Clinical and Translational Research, University of Kansas School of Medicine

See author’s profile
Mario Castro